Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app help kids with obesity stick to treatment?

NCT ID NCT06520787

Symptom relief Sponsor: Adhera Health, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a digital health program (Adhera Caring Digital Program®) combined with standard medication for 40 families of children aged 13-18 with obesity. The goal was to see if the program improved treatment satisfaction, adherence, and mood over one year. Participants used a smartwatch, received personalized messages, and had monthly check-ins with health coaches.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Adhera Caring Digital Program® (digital therapeutic software, personalized messages, educational materials) plus pharmacological treatment (orlistat, metformin, liraglutide, or semaglutide)
What this could lead to
If successful, this could show that combining a digital support program with medication helps families better manage childhood obesity, improving treatment satisfaction and adherence.
What could go wrong
This is a small feasibility study with only 40 families, so results may not apply to everyone. It focuses on short-term outcomes like satisfaction and mood, not long-term weight loss or health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

Mar 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The sample of the study (caregivers) will be recruited from the Pediatric Endocrinology unit at the Miguel Servet Children's University Hospital. This public hospital provides pediatric health attention to the regional area of Zaragoza (Spain), which covers a total of 367.110 inhabitants. Families of children with obesity that are already undergoing treatment and are willing to join a combined intervention.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Caregivers of children between 13 and 18 years who are diagnosed with obesity and undergoing treatment according to the approved label by AEMPS1 (adolescents with obesity aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex). * Families of children with obesity who have been under pharmacological treatment before screening. This includes treatment with any of the following medications orlistat, metformin, liraglutide, semaglutide. * Participants who are willing to join ACDP® for 10 months and can interact with a smartphone during that time. * The family is willing to complement the pharmacological obesity treatment with a digital intervention. * Participants (patients and their caregivers) must be willing to use wearables for the entire length of the study. * Parents previously using a wearable will agree not to use it during the length of the study, as their wearable account must be synched to the patient's device. Further, they may need to agree on changing the account data for height, weight, and gender in their Google account. Exclusion criteria: * Families not fluent in Spanish. * Families of children with obesity and comorbidities. * Families of children with secondary causes of obesity (i.e., hypothalamic, genetic or endocrine causes).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity, childhood are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Pediatric Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity, childhood

Contacts and locations

Locations

  • Hospital Universitario Miguel Servet

    Zaragoza, Aragon, 50009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.